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Cellular signalling cascades regulate the activity of tran-
scription factors that convert extracellular information
into gene regulation. C/EBPb is a ras/MAPkinase signal-
sensitive transcription factor that regulates genes involved
in metabolism, proliferation, differentiation, immunity,
senescence, and tumourigenesis. The protein arginine
methyltransferase 4 PRMT4/CARM1 interacts with
C/EBPb and dimethylates a conserved arginine residue
(R3) in the C/EBPb N-terminal transactivation domain,
as identiﬁed by mass spectrometry of cell-derived
C/EBPb. Phosphorylation of the C/EBPb regulatory domain
by ras/MAPkinase signalling abrogates the interaction
between C/EBPb and PRMT4/CARM1. Differential proteo-
mic screening, protein interaction studies, and mutational
analysis revealed that methylation of R3 constraines
interaction with SWI/SNF and Mediator complexes.
Mutation of the R3 methylation site alters endogenous
myeloid gene expression and adipogenic differentiation.
Thus, phosphorylation of the transcription factor C/EBPb
couples ras signalling to arginine methylation and
regulates the interaction of C/EBPb with epigenetic gene
regulatory protein complexes during cell differentiation.
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Introduction
The transcription factor C/EBPb is a member of the CCAAT/
enhancer-binding protein family that is composed of C/EBPa,
b, d, g, e, and z. C/EBPb is expressed in a variety of cell types
and participates in tissue-speciﬁc gene expression, prolifera-
tion, and differentiation in a hormone, cytokine, and nutrient-
dependent manner. C/EBPb controls important functions in
liver homeostasis, regeneration, acute phase response,
female reproduction, innate and adopted immunity, senes-
cence, and receptor tyrosine kinase/ras oncoprotein-
mediated tumourigenesis (Roesler, 2001; Farmer, 2006;
Sebastian and Johnson, 2006; Nerlov, 2007; Zahnow, 2009).
C/EBPb carries at its N-terminus a modular, composite
transactivation domain (TAD) that consists of four conserved
regions (CR1–4), a composite regulatory domain (RD) con-
sisting of CR5–7 at its centre that governs TAD functions, and
a basic DNA binding and leucine dimerization domain (bZip)
at the C-terminus (Kowenz-Leutz et al, 1994; Williams et al,
1995) (scheme in Figure 1A). Three C/EBPb protein isoforms
are expressed from a single, intronless transcript by signal-
dependent alternative translation initiation from in-frame
positioned start sites (Descombes and Schibler, 1991;
Calkhoven et al, 2000). These N-terminally variant C/EBPb
isoforms of 38, 35, and 20kDa are termed LAP*/C/EBPb1,
LAP/C/EBPb2, and LIP/C/EBPb3, respectively (Descombes
and Schibler, 1991; Bundy and Sealy, 2003).
The C/EBPb isoforms harbour distinct parts of the TAD
and RD and display diverse or even opposite gene regulatory
functions (Timchenko et al, 1999; Baer and Johnson, 2000;
Calkhoven et al, 2000; Eaton et al, 2001). The two long
isoforms (LAP*/C/EBPb1 and LAP/C/EBPb2) differ by a
conserved sequence of 21–23 N-terminal amino acids in
different species that represents CR1. CR1 functions as a
gene regulatory module involved in the recruitment of the
chromatin-remodelling SWI/SNF complex and the transcrip-
tion regulatory Mediator complex (Kowenz-Leutz and Leutz,
1999; Pedersen et al, 2001; Mo et al, 2004). The short isoform
(LIP/C/EBPb3) lacks the TAD and part of the RD and
represents a dominantly interfering protein that may neutra-
lize both, transactivation and transrepression by all C/EBPs
(Descombes and Schibler, 1991; Zahnow et al, 1997; Luedde
et al, 2004).
The transcriptional activity of C/EBPb is diversiﬁed by a
multitude of interactions with other C/EBP family members,
unrelated transcription factors, and transcription co-factors
(Sebastian and Johnson, 2006; Nerlov, 2008; Zahnow, 2009).
A major post-translational modiﬁcation has been attributed
to signalling through receptor tyrosine kinase–ras/mitogen-
activated protein kinase (MAPK) pathway that phosphory-
lates an evolutionary conserved MAPK consensus site in the
C/EBPb RD (Thr-235 in human (Nakajima et al, 1993),
Thr-188 in rat (Hanlon et al, 2001), Thr-220 in chicken
(Kowenz-Leutz et al, 1994)). In its non-phosphorylated
form, the RD of C/EBPb is involved in masking the TAD
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1105through intra-molecular interaction (Kowenz-Leutz et al,
1994; Williams et al, 1995) and in binding a repressive or
attenuated form of the Mediator complex. Phosphorylation of
the MAPK site is accompanied by a conformational change in
the protein, exchange of interacting Mediator components,
and transcriptional activation (Mo et al, 2004).
Alignment and sequence comparison of vertebrate C/EBPb
revealed a number of highly conserved arginine residues in
their N-termini that we considered to be involved in regulat-
ing C/EBPb activity. Here, we show that the TAD of C/EBPb
interacts with the protein arginine methyltransferase PRMT4/
CARM1 that methylates C/EBPbat the highly conserved arginine
residue at position 3 (R3) in CR1. Methylation of R3 is inversely
correlated to phosphorylation of the MAPkinase site in the
RD. The R3 methylation status determines the interaction
with the SWI/SNF complex and with the Mediator complex
to regulate endogenous target genes and cell differentiation
in an MAPkinase signalling-dependent manner.
Results
C/EBPb is methylated at arginine residues
Alignment and sequence comparison of vertebrate C/EBPb
family members revealed several conserved arginine residues
in low complexity regions of the N-terminus. We considered
the possibility that arginine side chains of C/EBPb are post-
translationally modiﬁed by methylation. As shown in
Figure 1B, the LAP*/C/EBPb1 isoform was immunoprecipi-
tated by an antibody speciﬁc to methylated arginine (Rme).
No Rme-speciﬁc immunoprecipitation was observed in the
presence of adenosine dialdehyde (AdOx, a homocysteine
hydrolase inhibitor that blocks the regeneration of the cellu-
lar methyl donor S-adenosyl methionine) (Bartel and
Borchardt, 1984; Chen et al, 2004). The two long C/EBPb
isoforms reacted with antibodies that speciﬁcally recognize
asymmetrically dimethylated arginine (ASYM24) or symme-
trically dimethylated arginine (SYM10) side chains
(Supplementary Figure 1). A small amount of the truncated
LIP/C/EBPb3 isoform was detected with the ASYM24 anti-
body, but not with SYM10 (Supplementary Figure 1B).
Metabolic labelling with L-[methyl-
3H]methionine in the
presence of cycloheximide and chloramphenicol revealed
tracer incorporation only in the long C/EBPb isoforms (data
not shown) (Pless et al, 2008). These results supported the
idea that C/EBPb is post-translationally modiﬁed by both,
asymmetrical and symmetrical dimethylation on arginines.
This notion was scrutinized by mass spectrometric analysis.
A histidine-tagged LAP*/C/EBPb1 construct was expressed
in ﬁbroblasts and enriched under denaturing conditions
by nickel chelating afﬁnity chromatography (Figure 1C).
C/EBPb fractions were digested to peptides, separated on
a nano-HPLC system and analysed by MS/MS mass spectro-
metry, as shown in Figure 1D. The mass shift (28m/z)o f
the modiﬁed R3 residue in the b-series of fragment ions
identiﬁed a dimethylated arginine at position 3. Multiple-
reaction monitoring (MRM) mass spectrometry from cell
lysates approved the occurrence of arginine dimethylation
on R3 of endogenous LAP*/C/EBPb1 in cells, as shown in
Supplementary Figure 2. As the N-terminally LAP*-speciﬁc
peptide has a clearly deﬁned modular function in chromatin
remodelling and gene regulation, we focused on the molecu-
lar biology and functions of C/EBPb R3 dimethylation;
Figure 1 C/EBPb is post-translationally methylated on arginine residues. (A) Scheme of C/EBPb isoforms that arise by alternative translation
initiation from in-frame start codons termed as LAP*/C/EBPb1, LAP/C/EBPb2 and LIP/C/EBPb3. (B) LAP*/C/EBPb1 is precipitated by the
ASYM24 anti-Rme2a antibody in the absence of AdOx. LAP*/C/EBPb1-transfected ﬁbroblasts were treated with adenosine dialdehyde (AdOx)
for 12h (as indicated) and immunoprecipitated with the ASYM24 antibody. Precipitated proteins were analysed by immunoblotting using an
anti-C/EBPb antibody. Right side shows expression controls in the absence and presence of AdOx. (C) Puriﬁcation scheme of C/EBPb. Brieﬂy,
His-tagged C/EBPb was puriﬁed under denaturing conditions by afﬁnity chromatography on a nickel chelating resin. Blot shows puriﬁed
fractions of C/EBPb.( D) Tandem mass spectrum of an R3me2 and oxidized N-terminal C/EBPb peptide. b- and y-series of the LysC-generated
peptides are indicated. Mass shifts indicate a 28Da modiﬁcation, corresponding to dimethylation at position R3. Underneath: alignment of
conserved region 1 (CR1) of LAP*/C/EBPb1 from various species shows conserved R3 (magenta box) and start sites (arrows) of the two long
isoforms.
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and will be described elsewhere (data not shown). Taken
together, the data showed that cellular C/EBPb is modiﬁed by
dimethylation of the conserved R3 (Figure 1D, lower part).
Proteomic screening reveals C/EBPb
R3 methylation-sensitive protein interactions
Protein interactions with non-modiﬁed and R3 asymmetri-
cally dimethylated peptides (aa 1–41) were analysed by
proteomic screening of a UNIPEX human cDNA expression
library that covers approximately one third of the human
proteome. Bacterially expressed His-tagged recombinant
proteins, immobilized in duplicates on PVDF membrane
were screened in replicate libraries with C-terminally bioti-
nylated peptides that encompassed C/EBPb CR1–2 with R3
either in its unmethylated or asymmetrically dimethylated
form (R3me2a), followed by detection with streptavidine
coupled to horseradish peroxidase, as shown in Figure 2A.
Numerous interactions detected with methylated and un-
methylated peptides fall into three distinct categories: protein
interactions with no preference for either peptide, interac-
tions that favoured R3 methylation, and interactions that
favoured unmodiﬁed R3 (data not shown). Thus, the methy-
lation status of C/EBPb R3 directs the interaction between
CR1 and other proteins.
Of particular interest was the interaction with two core
components of the SWI/SNF chromatin-remodelling com-
plex, Brg1 (Figure 2A) and BAF47/Ini1 (data not shown).
Both recombinant Brg1 and BAF47/Ini1 proteins interacted
preferentially with non-modiﬁed peptide and weakly with the
methylated peptide. Differential interaction between the SWI/
SNF complex and unmethylated versus dimethylated peptide
was conﬁrmed in pull-down assays with cell lysates, as
shown by retention of SWI/SNF subunits hBrm, BAF155,
and BAF47/Ini1 (Figure 2B). In addition, Mediator compo-
nents MED23/Sur2 and MED26 (not contained in the proteo-
mic library), earlier shown to interact with CR1, likewise
bound to unmodiﬁed LAP*/C/EBPb1 N-terminal peptide
(Figure 2B, bottom). These results are in accordance with
the earlier genetic and biochemical results (Kowenz-Leutz
and Leutz, 1999; Mo et al, 2004) and we conclude that
methylation of R3 affects the interaction with SWI/SNF and
Mediator complexes.
The effect of R3 modiﬁcations on protein complex binding
was examined by substituting R3 with alanine (R3A) or
leucine (R3L) to eliminate the methylation target or to
mimic increased hydrophobicity after methylation, respec-
tively. Immunoprecipitation and GST-pull-down assays with
LAP*/C/EBPb1 WT, R3A, and R3L mutants and SWI/SNF or
Mediator components (Supplementary Figure 3A and B)
showed preferential interaction of the R3A LAP*/C/EBPb1
mutant with hBrm and with the Mediator component MED23,
whereas R3L displayed decreased interactions with both
complexes. Thus, the R3A and the R3L C/EBPb1 mutant
proteins reﬂect the binding speciﬁcity of the screening
peptides and may serve as suitable tools for functional
investigations.
Alterations in R3 specify gene regulation
by LAP*/C/EBPb1
The interaction between CR1 and SWI/SNF is critical for the
activation of a subset of C/EBPb target genes, whereas other
C/EBPb target genes remain unaffected by CR1 (Kowenz-
Leutz and Leutz, 1999). Therefore, the effects of R3 mutations
were examined on the CR1-dependent endogenous myeloid
target gene mim-1 and the CR1-independent goose-type lyso-
zyme gene #325. As shown in Figure 3, the R3A LAP*/C/
EBPb1 mutant strongly activated endogenous mim-1 expres-
sion in comparison with WT LAP*/C/EBPb1 that can be
methylated at R3. In contrast, the R3L mutant was barely
active. Importantly, WTand both mutants activated the #325
gene to similar extends. Thus, the gene regulatory activity of
R3A and R3L mutants reﬂected CR1-speciﬁc co-factor inter-
actions and CR1 R3-speciﬁc functions on chromatin-
embedded target gene regulation.
PRMT4/CARM1 binds to and methylates C/EBPb
Lymphoid and myeloid cells that express C/EBPb also highly
express the protein arginine methyltransferases PRMT3,
PRMT4/CARM1 (both: asymmetric arginine metylation),
Figure 2 Differential interaction of SWI/SNFand Mediator complexes
with R3 methylated and unmethylated LAP*/C/EBPb1 N-terminal
peptides. (A) The N-terminal sequence of LAP*/C/EBPb1w a s
synthesized with R3 in unmodiﬁed form (1–41) or in asymmetri-
cally dimethylated form (1–41 Rme2a). Peptides with covalently
attached C-terminal biotin moieties (grey pentagons) were applied
to UNIPEX proteomic libraries and interactions were revealed by
streptavidin-HRP (SA-HRP) and ECL. Positive clones were identiﬁed
as characteristic duplicate pattern per square. Libraries contained
48x48 squares with four duplicate clones on two PVDF membranes.
A single square containing the brama-related gene 1 (Brg1) expres-
sion clone interacts with unmethylated, but not with methylated
peptide (arrow heads). (B) Unmethylated and methylated C/EBPb
peptides (1mM), as shown in (A) were incubated with cell lysates
and bound proteins separated by streptavidin Dynabeads. Cell
lysates were prepared from Raji cells (top) or HEK-293 MED23-
HA-transfected cell lysates (bottom). Western blots were incubated
with anti-hBrm, anti-BAF155, anti-BAF47/Ini1, anti-HA, and anti-
MED26 as indicated.
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therefore, examined whether R3 of the LAP*/C/EBPb1 iso-
form represents a target for one or more of these PRMTs.
PRMT3, 4, and 5 were transiently expressed in HEK-293 cells,
immunoafﬁnity puriﬁed from cell lysates, and incubated in
the presence of S-adenosyl-L-[methyl-
3H]methionine with
peptides P1, P2, P3, and P4, tiling the TAD of the rat
C/EBPb N-terminus (Figure 4A; P1: aa 1–21; P2: aa 22–56;
P3: aa 50–82; P4: aa 81–113). As shown in Figure 4B, radio-
activity was speciﬁcally incorporated with PRMT4/CARM1 in
P1, representing CR1 of LAP*/C/EBPb1. Label incorporation
was approximately 20-fold higher in P1 than in P2, P3, or P4
that also contained arginine and/or lysine residues. All three
PRMTs were equally expressed (Supplementary Figure 4A)
and functionally active, as determined by incorporation of
3H-methyl into recombinant GST-Histone H3 and H4 N-ter-
mini, but not into the GST moiety (Supplementary Figure
4B). These data show that PRMT4/CARM1 speciﬁcally
methylates the CR1 N-terminus of LAP*/C/EBPb1.
Methylation assays with the entire GST-C/EBPb TAD
(CR1–4; aa 1–113) showed that the C/EBPb-WT, but not the
R3A mutant TAD, was methylated by PRMT4/CARM1
(Figure 4C). The PRMT4/CARM1 enzyme activity and the
C/EBPb GST-protein expression were approved by auto-
methylation and protein staining, respectively (Supple-
mentary Figure 4C). In summary, these data conﬁrm R3 of
C/EBPb as a PRMT4/CARM1 methylation target.
Immunoprecipitation of C/EBPb from K562 cells revealed
that endogenous PRMT4/CARM1 and C/EBPb interacted in
myeloid cells (Figure 5A). Co-immunoprecipitations of WT
PRMT4/CARM1 or a catalytically inactive PRMT4/CARM1
mutant (amino-acids 189–191 VLD to AAA, dubbed PRMT4/
CARM1
mut) (Chen et al, 1999) with LAP*/C/EBPb1 showed
that interaction did not depend on the catalytic activity of
the methyltransferase (Supplementary Figure 5A). Deletion
mapping of C/EBPb revealed PRMT4/CARM1 association
with the C/EBPb TAD (Supplementary Figure 5B) and GST-
pull downs showed that PRMT4/CARM1 interacts preferen-
tially with C/EBPb TAD CR3 and CR4 (Supplementary
Figure 5C).
Examination of the functional consequences of PRMT4/
CARM1 interaction with C/EBPb showed that the catalyti-
cally defective PRMT4/CARM1
mut enhanced activation of the
myeloid LAP*/C/EBPb1 target gene mim-1, whereas WT
PRMT4/CARM1 decreased activation of mim-1 (Figure 5B).
Expression of the CR1-independent #325 myeloid gene re-
mained indifferent to WT PRMT4/CARM1 or its mutant,
excluding a general repressive effect of PRMT4/CARM1 on
the transcriptional machinery or on C/EBPb target genes.
Importantly, co-expression of WT PRMT4/CARM1 did not
suppress mim-1 activation by the non-methylatable C/EBPb1
R3A mutant (Figure 5B, right), providing further evidence
that methylation of R3 speciﬁcally interferes with the activa-
tion of LAP*/C/EBPb1 CR1-dependent target genes. The
results suggest that the methylation status of the R3 side
chain has a decisive function in the regulation of SWI/SNF
complex-dependent target genes.
C/EBPb phosphorylation abrogates PRMT4/CARM1
interaction
C/EBPb is a repressed transcription factor that can be acti-
vated by EGF receptor tyrosine kinase and ras signalling
through the MAP kinase Erk1/2 pathway (Nakajima et al,
1993; Kowenz-Leutz et al, 1994; Fan et al, 2009).
Phosphorylation of the conserved MAP kinase site in the
Figure 4 PRMT4 methylates the N-terminus of C/EBPb.( A)S c h e m e
of C/EBPb N-terminal peptides and C/EBPb N-terminal GST-protein.
(B) In vitro methylation of C/EBPb N-terminal peptides by PRMT3,
PRMT4/CARM1, and PRMT5. HA-tagged PRMT3, 4, and 5 were
expressed in HEK-293 cells, puriﬁed from cell lysates by immuno-
precipitation with anti-HA and incubated with 1mMo ft h ec o r r e s p o n d i n g
peptides as substrates in the presence of L-[methyl-
3H]methionine
as a
3H-methyl-donor. Bars represent relative incorporation of labelled
S-adenosyl-L-[methyl-
3H]methionine. (C) In vitro methylation of
recombinant C/EBPb N-terminal GST proteins by PRMT4/CARM1.
Reactions were carried out as described in (B) with 3mg GST protein
as a substrate. Bars represent relative incorporation of labelled
S-adenosyl-L-[methyl-
3H]methionine. Histone H3 was used as a
positive and the GST moiety as a negative control for PRMT4/
CARM1-speciﬁc L-[methyl-
3H]methionine labelling.
Figure 3 LAP*/C/EBPb1 R3 mutations alter C/EBPb target gene
activation. LAP*/C/EBPb1 constructs were transfected into QT6
ﬁbroblasts as indicated. RNA was extracted 18h post-transfection
and subjected to serial northern hybridization to probes directed to
the mim-1 gene, #325 gene, and GAPDH as a control.
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change in C/EBPb that alters interactions with protein com-
plexes (Kowenz-Leutz et al, 1994; Williams et al, 1995;
Mo et al, 2004). We, therefore, examined whether ras signalling
also alters interaction between PRMT4/CARM1 and C/EBPb.
As shown in Figure 6A, co-expression of activated ras
V12 with
C/EBPb increased phosphorylation at the MAPkinase site.
Concomitantly, binding of PRMT4/CARM1 to C/EBPb was
diminished. Immunoprecipitation of endogenous C/EBPb
from K562 cells approved that PRMT4/CARM1 interacts with
C/EBPb in untreated, but not in phorbol ester (phorbol-12-
myristate-13-acetate, PMA)-treated cells (Figure 6B). MRM
of endogenous C/EBPb from K562 cells showed inverse
correlation between phosphorylation of the MAPK-site and
dimethylation of R3 of LAP*/C/EBPb1 and disappearance of
R3 methylation after PMA treatment (Figure 6C).
Earlier, it was reported that EGF receptor tyrosine kinase
signalling inhibits PRMT4/CARM1 methyltransferase activity
and subsequent histone H3 methylation (Higashimoto et al,
2007). We, therefore, examined whether activated C/EBPb,a s
represented by the LAP*/C/EBPb1 phospho-mimetic MAP-
kinase site mutant T220D, interacts with PRMT4/CARM1. As
shown in Figure 6D, interaction between PRMT4/CARM1 and
C/EBPb T220D was strongly diminished, as compared with
WT C/EBPb. In accordance, the C/EBPb T220D mutant
activated adipogenic target gene expression and fat cell
differentiation, as compared with WT, whereas the C/EBPb
T220A displayed strongly diminished activity (Supple-
mentary Figure 7). Taken together, these results suggested
that phosphorylation of the C/EBPb RD abolishes the inter-
action between the TAD of C/EBPb and PRMT4/CARM1 and
as a consequence leads to abrogation of methylation of R3
LAP*/C/EBPb1.
Alteration of the LAP*/C/EBPb1 R3 residue affects
myeloid and adipogenic differentiation
C/EBPb associates with the human neutrophil elastase gene
(hELA2) and activates hELA2 expression in an MAPkinase
signal-dependent manner (Nuchprayoon et al, 1997; Lausen
et al, 2006; Pless et al, 2008). Myeloid gene activation in
heterologous cells and reprogramming by C/EBPb are well
established (Laiosa et al, 2006; Zahnow, 2009). Therefore, we
examined whether the myeloid hELA2 gene can be activated
by LAP*/C/EBPb1 in ﬁbroblasts. Expression of hELA2 in NIH
3T3 ﬁbroblasts was strongly enhanced after PMA treatment
with LAP*/C/EBPb1, but not with LAP/C/EBPb2 or LIP/C/
EBPb3. The LAP*/C/EBPb1 R3A mutant was signiﬁcantly
more active than WT LAP*/C/EBPb1, yet barely induced by
PMA (Figure 7A, expression controls in 7B). These data are
consistent with the rational that R3 in its unmethylated and
methylated form is involved in activation and repression
processes and that replacement of R3 (R3A) partially com-
promises both functions. The LAP*/C/EBPb1 R3L mutant
did not display signiﬁcant activity with or without PMA,
consistent with the notion that replacement of R3 with
leucine stabilizes the inhibitory state of LAP*/C/EBPb1.
These data show that CR1 of LAP*/C/EBPb1 has an impor-
tant function in the activation of the endogenous hELA2
gene in ﬁbroblasts.
Endogenous C/EBPb in human U937 myeloid cells binds to
a 117bp fragment upstream of the hELA2 TATA-box
(Nuchprayoon et al, 1997; Lausen et al, 2006) and PMA-
induced phosphorylation of the C/EBPb MAPkinase site
upregulates hELA2 expression (Pless et al, 2008). As shown
in Figure 7C, both C/EBPb and PRMT4/CARM1 were found
associated with the hELA2 promoter in U937 cells. Reciprocal
re-immunoprecipitation of either C/EBPb or PRMT4/CARM1
conﬁrmed simultaneous occupancy of the hELA2 promoter
(Supplementary Figure 6). PMA treatment abrogated associa-
tion of PRMT4/CARM1 with the hELA2 promoter, whereas
C/EBPb occupancy persisted (Figure 7C). In addition, the
Mediator complex component MED23/Sur2 was associated
with the hELA2 promoter before PMA stimulation and in-
creased after PMA treatment. In contrast, CDK8, a component
of attenuated Mediator, was ﬁve-fold decreased after PMA
treatment, probably reﬂecting the earlier described exchange
between Mediator complex modules (Mo et al, 2004). Taken
together, these data support the notion that C/EBPb phos-
phorylation is accompanied by dissociation from PRMT4/
CARM1 and loss of the Mediator CDK8 module during hELA2
gene activation.
C/EBPb also regulates adipogenesis and controls early
activation of a cascade of transcription factors that ﬁnally
orchestrate adipogenic differentiation (Cao et al, 1991; Wu
et al, 1995; Yeh et al, 1995; Mandrup and Lane, 1997; Birsoy
Figure 5 Physical and functional interaction between C/EBPb and
PRMT4/CARM1 in eukaryotic cells. (A) K562 cell lysates were
incubated with antibodies (IgG, negative control) or anti-C/EBPb
and antigen–antibody complexes were immunoprecipitated.
Proteins were analysed by immunoblotting with anti-PRMT4/
CARM1 or anti-C/EBPb as indicated. IB: immunoblot. (B) LAP*/
C/EBPb1 WT or R3A constructs, as indicated, were transfected in
QT6 ﬁbroblasts together with WTor PRMT4/CARM1
mut constructs.
RNA blots were subjected to serial hybridization to the mim-1, #325
and GAPDH gene probes.
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essential prerequisite for induced onset of the adipogenic
program (Pedersen et al, 2001; Caramel et al, 2008). We,
therefore, asked whether stable expression of WTand mutant
LAP*/C/EBPb1 isoforms in NIH 3T3 L1 cells alters adipogen-
esis. As shown in Figure 7E (expression controls Figure 7F),
fat cell differentiation was strongly enhanced by the LAP*/C/
EBPb1 R3A mutant, as indicated by upregulation of the
adipogenic genes PPARg, aP2, and adipsin (Figure 7D), in
the absence of the usually required hormone cocktail. In
contrast, expression of the LAP/C/EBPb2 isoform or the
LAP*/C/EBPb1 R3L mutant in NIH 3T3 L1 cells did not
induce spontaneous differentiation. These results suggest
that enhanced SWI/SNF recruitment by unmethylated R3 in
LAP*/C/EBPb1 CR1 predisposes mesenchymal precursor
cells to adipogenic differentiation.
Discussion
The transcription factor C/EBPb functions at the interface
of cell metabolism, stress, proliferation, and differentiation.
Data presented here show that ras/MAPkinase signalling
is coupled to R3 methylation and that the R3 methylation
state speciﬁes interactions between C/EBPb, SWI/SNF
and Mediator. Our data show how extracellular signals
initially converted to kinase signalling connect to arginine
methylation of a transcription factor that in turn determines
interaction with the epigenetic and gene regulatory machinery
in the nucleus to regulate gene transcription and differentia-
tion. The data are summarized in the conceptual model
shown in Figure 8.
A distinctive feature of the intronless single C/EBPb tran-
script is that alternative translation initiation at consecutive
in-frame start sites may generate three protein isoforms with
different N-termini that display activator and repressor func-
tions (Descombes and Schibler, 1991; Calkhoven et al, 2000).
The CR1 comprises 21–23 amino acids in different species
and is contained in the largest LAP*/C/EBPb1 isoform.
LAP*/C/EBPb1 regulates a subset of C/EBPb target genes
that are involved in mammary epithelial integrity, prolifera-
tion and cell differentiation, innate immunity, and potentially
also fat metabolism (Eaton et al, 2001; Bundy and Sealy,
Figure 6 Effect of ras/MAPkinase signalling or a phospho-mimetic mutation on the interaction between C/EBPb and PRMT4/CARM1.
(A) FLAG-tagged LAP*/C/EBPb1 was co-expressed with HA-tagged PRMT4/CARM1 in QT6 ﬁbroblasts in the absence and presence of ras
V12.
Immunoprecipitation (IP) from cell lysates with anti-Flag or anti-HA antibody as indicated (top) and protein expression control (below, expr.
control). The anti-P-Thr235 antibody speciﬁcally reveals C/EBPb that is phosphorylated at the MAPkinase site. IP: immunoprecipitation. IB:
immunoblot. (B) Lysates from K562 cells (with/without PMA treatment) were immunoprecipitated with anti-C/EBPb or negative control IgG.
Proteins were analysed by immunoblotting with anti-PRMT4/CARM1, anti-C/EBPb, or anti-P-Thr235, as indicated. Protein expression control
below (expr. contr.). IP: immunoprecipitation. IB: immunoblot. (C) Relative quantiﬁcation of phosphorylation and R3me2 on LAP*/C/EBPb1
by multiple-reaction monitoring (MRM). Left: three different tryptic peptides were used for quantiﬁcation of C/EBPb in total cell lysates
from untreated and PMA-treated K562 cells, as indicated. Middle: quantiﬁcation of the C/EBPb Thr-235 phosphorylation MAPkinase site
containing tryptic C/EBPb peptide. Right: quantiﬁcation of the R3-LAP*/C/EBPb1 methylated tryptic peptide in total cell lysates by MRM.
(D) FLAG-tagged LAP*/C/EBPb1 or LAP*/C/EBPb1 T220D constructs were co-expressed with HA-tagged PRMT4/CARM1 in QT6 ﬁbroblasts.
Cell lysates were immunoprecipitated with anti-HA and immunoblots (IP) were developed with anti-Flag or anti-HA, respectively (indicated on
the right). IP: immunoprecipition. IB: immunoblot. Below: protein expression control (anti-Flag or anti-HA) as indicated. Vertical lines indicate
assembly of two separated lanes on the same immunoblot.
Crosstalk implies an indexing transcription factor code
E Kowenz-Leutz et al
The EMBO Journal VOL 29 | NO 6 | 2010 &2010 European Molecular Biology Organization 11102003; Uematsu et al, 2007). Our data show that the conserved
arginine at position 3 (R3) can be speciﬁcally methylated by
PRMT4/CARM1 and that the methylation status of R3 deter-
mines the interaction between CR1 and other proteins.
Proteins that interact with the unmethylated CR1 include
components of the SWI/SNF complex and Mediator complex.
Both multi-subunit protein complexes had been described
earlier to mediate important functions of LAP*/C/EBPb1
isoforms during chromatin remodelling and gene regulation.
Mass spectrometry combined with mutational analysis,
biochemical, molecular genetic, and cell biological data
establishes that PRMT4/CARM1 interacts with the TAD of
C/EBPb and dimethylates CR1 speciﬁcally at the evolutionary
conserved R3 residue. Methylation of R3 impairs the interac-
tion with SWI/SNF and Mediator complexes and, therefore,
attenuates activation of myeloid and adipogenic genes. It has
recently been shown that adipogenic induction requires
activation of C/EBPb expression and that the LAP* isoform
was able to bypass an early regulatory network of pro-
adipogenic transcription factors (Birsoy et al, 2008). At the
same time, genes that are not affected by the presence of CR1
are exempt from R3 regulation. This interpretation is in
agreement with a modular and appendicular function of N-
terminal CR1 (Pedersen et al, 2001) and is supported by a
recent knock in study that shows that LAP*/C/EBPb1 may
largely replace LAP/C/EBPb2 (Uematsu et al, 2007).
Of particular attention is the ﬁnding of a functional cross-
talk between ras/MAPkinase signalling, arginine methylation
of C/EBPb and recruitment of an epigenetic complex. Our
data show that phosphorylation of a distal site and methyla-
tion of the N-terminal R3 has opposing functions on C/EBPb-
mediated gene activation. The interaction between PRMT4/
CARM1 and C/EBPb and their co-association on the hELA2
promoter is abolished when LAP*/C/EBPb1 is phosphory-
lated. Concomitantly, the silent myeloid hELA2 C/EBPb target
gene was activated in ﬁbroblasts, reﬂecting epigenetic activa-
tion of myeloid gene expression by LAP*/C/EBPb1. The R3A
mutation in C/EBPb that removes the methylation target
displayed enhanced co-factor interactions, myeloid gene acti-
vation, induction of adipogenesis, and, importantly, resists
the repressive effect of PRMT4/CARM1. We conclude that in
the absence of signals, association of PRMT4/CARM1 speci-
ﬁcally restrains LAP*/C/EBPb1 functions by R3 methylation,
without repressing the overall C/EBPb activity.
Earlier, we had shown that C/EBPb is also methylated on a
highly conserved lysine residue by G9a and that methylation
at K39 compromised its transactivation (Pless et al, 2008).
Here, we show that MAPkinase-phosphorylated C/EBPb is
undermethylated. Accordingly, our data support the idea of
a negative crosstalk between C/EBPb phosphorylation and
methylation and raise the possibility that in the absence
of an activating signal, C/EBPb becomes methylated and
remains transcriptional inactive or displays repressor functions,
whereas MAPkinase signalling transiently abrogates C/EBPb
methylation and permits co-activator recruitment and gene
activating functions.
Phosphorylation of the RD following receptor tyrosine
kinase–ras/MAPK signalling has been shown to activate
LAP*/C/EBPb1 by inducing a structural change that affects
interaction and composition of associated Mediator complex
(Mo et al, 2004). Data presented here suggest that phospho-
rylation of the C/EBPb RD also curtails interaction with
PRMT4/CARM1 that is associated with inactive C/EBPb.I n
Figure 7 Myeloid and adipogenic gene regulation. (A) Expression
of neutrophile elastase (hELA2) transcripts by C/EBPb isoforms in
NIH 3T3 cells before and after PMA treatment. NIH 3T3 cells were
transfected with constructs (as indicated) and after 24h stimulated
with phorbol ester (PMA) for 1.5h. Total mRNA and cDNA were
prepared and hELA2 gene expression was analysed by RT–PCR and
normalized to GAPDH expression. (B) Expression control of
C/EBPb isoforms detected by immunoblotting. (C) ChIP assay
from either unstimulated or PMA-stimulated U937 cells.
Antibodies were used as indicated. Quantitative PCR results are
shown as fold binding compared with the IgG control. (D)
Activation of PPARg, aP2, and adipsin expression by LAP*/C/
EBPb1, LAP/C/EBPb2 isoforms, and the LAP*/C/EBPb1 R3A or
R3L mutants in NIH 3T3 L1 cells in the absence of adipogenic
differentiation hormone cocktail. NIH 3T3 L1 cells were transfected
with vector, LAP*/C/EBPb1, LAP/C/EBPb2, LAP*/C/EBPb1 R3A,
and LAP*/C/EBPb1 R3L and stable transfectants selected by puro-
mycin. Cells were grown to conﬂuency and total mRNA and
cDNAs were prepared 10 days after conﬂuency. The results were
normalized to GAPDH expression. (E) Oil red O staining of stably
transfected cells, ten days post-conﬂuency, as shown in (D).
(F) Protein expression control of cells as shown in (D).
Figure 8 Model of crosstalk between phosphorylation and R3
methylation of C/EBPb.
Crosstalk implies an indexing transcription factor code
E Kowenz-Leutz et al
&2010 European Molecular Biology Organization The EMBO Journal VOL 29 | NO 6 | 2010 1111this context, it is interesting to note that in studies of
promoter-speciﬁc PRMT4/CARM1 functions, enhanced ex-
pression of the C/EBPb target genes Il6 and COX2 (Akira
et al, 1990; Poli, 1998; Gorgoni et al, 2001) was observed in
CARM1-deﬁcient cells (Covic et al, 2005), supporting an
inhibitory function of CARM1 for distinct C/EBPb functions.
PRMT4/CARM1 is primarily considered in gene transacti-
vation; however, a repressive function on gene transcription
has also been described for the histone acetyltransferase
CREB-binding protein that when methylated at the KIX
domain failed to interact with the transcription factor
CREB. In addition, methylation of the steroid receptor co-
activator 3 complex leads to co-activator disassembly and
decreased steroid receptor-mediated transcription (Xu et al,
2001; Feng et al, 2006). Co-activator functions of PRMT4/
CARM1 were described for nuclear hormone receptor-
mediated target gene activation, including PPARg-mediated
adipogenesis, which is reduced by 40% in adipose tissue in
PRMT4/CARM1 KOs (Yadav et al, 2008). It, therefore, seems
that the activity of PRMT4/CARM1 is dispensable for the
early activation of adipogenic co-factors (supported by data
shown in Supplementary Figure 8), whereas PRMT4/CARM1
is required as a co-activator for PPARg functions in terminal
differentiation. In support of this notion is the observation
that MAPkinase signalling and IBMX (enhances protein
kinase-A signalling) supports early, but not late, adipogenic
differentiation (Student et al, 1980; Kortum et al, 2005).
A function of PRMT4/CARM1 is the methylation of histone
H3 at R17 (Ma et al, 2001; Bauer et al, 2002; Yadav et al,
2003). Although PRMT4/CARM1 is not the only H3R17-
speciﬁc methyltransferase, it would have been informative
to monitor the H3R17 methylation status in the vicinity of
C/EBPb-binding sites in the genome. Unfortunately, attempts
to determine the H3R17 methylation status failed, as avail-
able R17 methylation-speciﬁc antibodies were found to cross-
react with methylated C/EBPb (data not shown). A more
detailed analysis of chromatin structure and C/EBPb R3
methylation must, therefore, await the availability of more
speciﬁc reagents that discriminate between histone and
C/EBPb R3 modiﬁcation states.
Interaction between the N-terminus of LAP*/C/EBPb1 and
the SWI/SNF complex was originally detected in chromatin-
remodelling deﬁcient yeast and conﬁrmed biochemically and
molecular genetically in vertebrate cells (Kowenz-Leutz and
Leutz, 1999). Differential interaction of SWI/SNF complex
proteins was now found again by proteomic screening with
peptides that represent unmethylated and methylated deriva-
tives of the LAP*/C/EBPb1 N-terminus. These data conﬁrm a
modular function of CR1 in SWI/SNF recruitment and show
the feasibility of proteomic expression screening approaches
with transactivation modules that contain or lack post-
translational modiﬁcations to uncover differential protein
interactions.
Methylation of arginine side chains may either enhance
interactions by increasing hydrophobicity or act as a hydro-
gen donor (for review see Dacwag et al, 2009; Lee and
Stallcup, 2009), although more often abrogation of interac-
tions between proteins has been observed. For example, it
has been shown that methylation of RUNX1 by PRMT1
interferes with binding of the SIN3A complex, thus leading
to gene activation by removal of an inhibitor (Zhao et al,
2008). However, our proteomic screening results support the
notion that methylation of R3 not only abrogates interactions,
but also enhances protein interactions. Whether or not such
interactions through R3 contribute to gene silencing effects by
LAP*/C/EBPb1 is currently under investigation.
In addition to modiﬁcations at R3, C/EBPb may carry a
multitude of modiﬁcations including phosphorylation, acet-
ylation, lysine, and arginine methylation at different sites,
similar to the well-studied example of p53 (Yang, 2005;
Olsson et al, 2007; Scoumanne and Chen, 2008). We, there-
fore, assume in analogy to a ‘histone code’ (Turner, 1998,
2000; Jenuwein and Allis, 2001) a ‘transcription factor code’
of modiﬁcations that tunes transregulatory functions (Sims
and Reinberg, 2008). C/EBPb might serve as a signal-depen-
dent docking platform for epigenetic enzymes that once
recruited may also alter the functionality of C/EBPb by
decoration with additional PTMs that, in further analogy to
the histone code, may serve as docking/blocking/assembly
sites for novel-interacting complexes. This notion has
medical, pharmacological, and developmental implications,
as ‘epigenetic drugs’ might not only affect histone/chromatin
modiﬁcations, but also transcription factor functions. The
technical advance shown here, combining mass spectrometry
with PTM-dependent proteomic screening, will help to estab-
lish a more general insight into the succession, interdepen-
dence, and functions of signal-dependent PTM patterns on
C/EBPb and interacting protein complexes.
Materials and methods
Peptides
C/EBPb peptides covering the TAD were synthesized and are
derived from the mouse sequence (Swiss-Prot P28033)—peptide 1:
aa 1–21; peptide 2: aa 22–55; peptide 3: aa 49–81; peptide 4: aa
80–113. For protein macroarray screening and peptide pull-down
analysis, two peptides were synthesized and HPLC puriﬁed cover-
ing aa 1–41 in a non-methylated and R3 asymetrically dimethylated
form (PSL).
Protein macroarray screening (UNIPEX)
Two identical UNIPEX protein macroarrays (containing approxi-
mately 20000 sequenced, annotated and veriﬁed cDNA clones;
ImaGenes, Berlin) were overlayed with non-modiﬁed and R3
asymmetrically dimethylated N-terminal C/EBPb peptides covering
aa 1–41. In brief, protein macroarrays were rinsed in water, washed
with TBS-T-T (500mM NaCl, 20mM Tris HCl (pH 7.5), 0.05%
Tween 20, 0.5% Triton X-100) and excess bacterial colony material
was scraped off the macroarray. Subsequently, membranes were
blocked with 3% skim milk in TBS-T (500mM NaCl, 20mM
Tris HCl (pH 7.5), 0.05% Tween 20) for 2h. The libraries were
incubated with 1mM for both, unmodiﬁed and modiﬁed peptides, in
blocking solution over night. Interaction partners were detected by
using streptavidin-HRP and ECL. Positive scoring clones were
localized, according to the manufacturer’s instructions.
Peptide pull down
Streptavidin dynabeads were saturated with non-modiﬁed or R3
asymmetrically dimethylated N-terminal C/EBPb peptides for
30min in PBS (pH 7.4). Excess peptides were washed off with
wash buffer (PBS (pH 7.4), 0.01% Tween, 0.1% BSA). Beads were
then incubated with cell extracts prepared from Raji or HEK-293
cells for 1h (lysis buffer: 20mM Hepes (pH 7.6), 350mM NaCl,
30mM MgCl2, 1mM EDTA (pH 8), 0.1mM EGTA (pH 8), 20%
glycerol, 0.5% NP40). After washing, bound proteins were eluted
with SDS–PAGE loading buffer. Western blots were incubated with
appropriate antibodies and revealed by ECL.
In vitro methylation
PCDNA3.1-HA PRMT3, 4, or 5 were transfected into HEK-293 cells;
48h post transfection, cells were lysed (50mM Tris pH 8, 150mM
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inhibitors) and immunoprecipitations were performed from lysates
with anti-HA for 3h. Immunocomplexes were coupled to protein
G-coated Dynabeads (Invitrogen) for 1h, washed with lysis buffer
and used directly in in vitro methylation studies. Reactions were
carried out in PBS, supplemented with 1mCi of S-adenosyl-L-
(methyl-
3H)methionine as methyl donor and incubated with either
1mM of corresponding peptides or 1–2mg of C/EBPb GST-fusion
proteins for 3h at 301C. Three parts of the reaction was submitted to
SDS–PAGE, methylated proteins were detected by ﬂuorography, and
one part of the reaction was spotted on phosphocellulose
membrane to determine [
3H]methyl incorporation by scintillation
counting.
Mass spectrometry
pcDNA3-NFM-8xHis constructs were transiently transfected, ex-
pressed in QT6 quail ﬁbroblasts, and extracted under denaturing
conditions in lysis buffer (100mM NaH2PO4 (pH 8.0); 10mM
Tris HCl (pH 8.0); 6M guanidine-HCl; 20mM Imidazole; 1mM
Tris(2-carboxyethyl)phosphine; 1mM Pefabloc; 40mg/ml Bestatin;
protease inhibitor cocktail (Roche)). Afﬁnity puriﬁcation was
carried out on an A ¨KTA puriﬁer (GE Healthcare) equipped with
a HisTrap HP Nickel column (GE Healthcare). Elution was
performed with an Imidazole gradient (20–250mM). For the
identiﬁcation of arginine methylation on C/EBPb, peptides were
generated using Lysyl-endopeptidase (LysC) as described (de
Godoy et al, 2008). Peptides were separated by reverse phase
chromatography on a nano-Acquity UPLC (Waters) and analysed by
electrospray ionization on a Q-TOF premier mass spectrometer
(Waters). Peptide spectra were assigned using the MASCOT
software (Matrix Science) and reﬁned by hand interpretation.
For quantiﬁcation of endogenous C/EBPb R3 modiﬁcation by
MRM of untreated or PMA-treated K562 or U937, cell lysates
were prepared in 6M Urea, 2M Thiourea, 10mM HEPES
(pH 8.0), 1mM Pefablock, and protease inhibitor cocktail (Roche).
Fragment ion spectra were obtained by fragmenting an arginine
R3 dimethyl-modiﬁed hC/EBPb N-terminal peptide. The peptide
was injected into mass spectrometer using electrospray ioniza-
tion. Fragment spectra were recorded in an MDS/Sciex AB 5500
Q-TRAP mass spectromenter and analysed with the Analyst 1.5
Software (Applied Biosystems). Signature fragments were selected
for the creation of a MRM method; 5mg of total cells extract
were recorded with dwell times ranging from 5 to 100ms.
The intensities were integrated with the MRMPilot Software
package (Applied Biosystems) and normalized to the actin measure-
ment. Statistical analysis was performed using the R software
package (V2.10).
Cell culture and transfection
C33A, HEKT-293, NIH 3T3, and NIH 3T3 L1, MEF  /þ PRMT4/
CARM1 cells were grown in Dulbecco’s modiﬁed Eagle medium
(DMEM; Invitrogen) supplemented with 10% FCS (Invitrogen) and
QT6 cells were grown in DMEM containing 8% FCS and 2% heat-
inactivated chicken serum (Invitrogen). Raji, U937, and K562 cells
were cultured in RPMI (Invitrogen) containing 10% FCS. All media
were supplemented with 1% penicillin/streptomycin and cells were
grown at 5% CO2,3 7 1C. Transient transfections were performed by
calcium-phosphate precipitation or Metafectene (Biontex) accord-
ing to the manufacturer’s protocol.
Endogenous gene activation assay and northern blot analysis
Resident gene activation was determined after transient transfection
of indicated constructs in QT6 ﬁbroblasts as described earlier
(Kowenz-Leutz et al, 1994). Brieﬂy, total RNA was extracted by
the guanidinium-isothiocyanate method, selected by magnetic
oligo(dT) beads (Dynal), RNA was separated on 1.2% formalde-
hyde-agarose gel, transferred to nylon membrane (Hybond
N
þ, Amersham),
32P-labelled probes to mim-1, #325 or GAPDH
transcripts were hybridized in series to ﬁlters in Quik-Hyb
hybridization solution (Stratagene) as indicated.
Plasmid constructs
Construction of C/EBPb expression plasmids is based on the
chicken sequence (accession number EMBL Z21646). The LAP*/C/
EBPb1 start site was altered by exchange of glutamine to glutamic
acid at position 2 to generate an optimized Kozak consensus
sequence. C/EBPb-conserved regions and corresponding amino
acids in C/EBPb were published earlier (Kowenz-Leutz et al, 1994).
Brieﬂy, CR1 corresponds to AA 1–13; CR2 to AA 18–38; CR3 to AA
42–63; CR4 to AA 99–113; CR5 to AA 184–222; CR6 to AA 145–179;
CR7 to AA 184–222, and CR8–9 (bZIP region) to AA 243–317.
C/EBPb mutations were introduced by site-directed mutagenesis
using the QuikChange site-directed mutagenesis kit (Stratagene)
and conﬁrmed by sequencing.
GST constructs were cloned from PCR fragments derived from
C/EBPb or Histone H3 and H4 N-terminal tails as described earlier
(Kowenz-Leutz and Leutz, 1999; Mo et al, 2004). All PRMT
plasmids were generated by RT–PCR from HEK-293 or K562 cell
cDNAs. PRMT3 was subcloned as BamHI/XhoI Fragment and
PRMT4/CARM1 and PRMT5 expression plasmids were cloned as
BamHI/EcoRI Fragments in pCDNA3.1-HA (Invitrogen).
PRMT3 primer: 50-ATAGGATCCATGTGCTCGTTAGCGTCAGGC and
30-TATCTCGAGTCACTGGAGACCATAAGTTTG. CARM1 primer: 50-TG
GGATCCCCGATGGCAGCGGCGGCAGCGGCG and 30-CGGAATTCGC
TCCCGTAGAGCATGGTGTTGGT. PRMT5 primer: 50-CGCGGATCCGT
GATTGGCTACTAGTATCAAGGAATCCCGGCGTGGACA and 30-CGGG
AATTCCTAGAGGCCAATGGTATATGA. CARM1
VLD189 191 mutant
was constructed as described (Chen et al, 1999).
GST-pull-down experiments
Bacterial expression and preparation of GST-fusion proteins was
performed according to standard procedures. For pull-down assays,
GST-fusion proteins were bound to Glutathione sepharose 4B and
incubated with in vitro translated MED23 or PRMT4/CARM1
(TNT-Kit, Promega).
Immunoprecipitation and immunoblotting
Immunoprecipitations of C/EBPb and hBrm, expressed in C33A
cells, were performed as described (Kowenz-Leutz and Leutz,
1999). Brieﬂy, cell lysates were prepared in lysis-buffer A (20mM
Hepes (pH 7.9), 350mM NaCl, 30mM MgCl2, 1mM EDTA (pH 8),
0.1mM EGTA (pH 8), 20% glycerol, 0.5% NP40, supplemented
with protease inhibitor cocktail (Roche Applied Bioscience)). For IP,
lysates were diluted with Buffer B (20mM Hepes (pH 7.9), 30mM
MgCl2, 1mM EDTA pH 8, 1mM EGTA pH 8, 20% glycerol, 0.2%
NP40). Immunoprecipitations of CARM1 and hBrm were performed
in lysis buffer 50mM Tris (pH 8), 150mM NaCl, 0.5% NP40, 1mM
EDTA (pH 8) supplemented with protease inhibitor cocktail.
Samples were immunoprecipitated with appropriate antibodies for
2–3h at 41C as indicated and immunoprecipitates were collected on
protein A- or G-Sepharose beads. Immunoprecipitations of C/EBPb
constructs and PRMT4/CARM1 were performed after transient
transfection of QT6 ﬁbroblasts, HEK-293 cells, or K562 cells for
endogenous protein interaction studies. Brieﬂy, cells were lysed in
buffer (50mM Tris (pH 8), 150mM NaCl, 0.5% NP40, 1mM EDTA,
and protease inhibitors). Samples were immunoprecipitated with
appropriate antibodies for 2h at 41C as indicated and immuno-
precipitates collected on protein A- or G-Sepharose beads. Antibodies:
anti-C/EBPb (Leutz lab), anti-C/EBPb (Santa Cruz; C-19, H-7),
anti-phospho-Thr235 C/EBPb (Cell Signaling Technology; #3084),
anti-FLAG (Sigma), anti-HA.11 (Covance), anti-ASYM24 (Upstate;
07-414), anti-SYM10 (Upstate; 07-412), anti-methyl Arginine
(Abcam; ab412), anti-PRMT4/CARM1 (Cell Signaling Technology;
#4438), anti-Brm (Biomol; A301-014A), anti-BAF155 (Biomol;
A301-019A), anti-BAF47/Ini1 (Sigma; H9912), anti-MED23 (Santa
Cruz; SC-12454), anti-MED26 (Santa Cruz; SC-9425), and anti-
CDK8 (Santa Cruz; SC-1521). Immunoblots were visualized by
ECL (GE Healthcare).
Chromatin immunoprecipitation
Chromatin immunoprecipitations with subsequent quantitative
PCR of the hELA2 gene promoter and IgG control were performed
as described (Pless et al, 2008). Re-ChIP analysis was performed
using the ‘Re-ChIP-IT Magnetic Chromatin Re-immunoprecipitation
kit’ (Active Motif, #53016) according to the manufacturer’s
protocol.
Adipogenesis and RT–PCR analysis
Vector control, LAP*/C/EBPb1, LAP/C/EBPb2, LAP*/C/EBPb1
R3A, or LAP*/C/EBPb R3L were transfected by Metafectene
according to the manufacturer’s protocol (Biontex) in NIH 3T3 L1
ﬁbroblasts and selected by 1.5mg/ml puromycin. Stable trans-
fectans were seeded in triplicates on tissue culture dishes and
grown to conﬂuency. Ten days past conﬂuency, total RNA was
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and cDNA was prepared using SuperScript cDNA Kit (Invitrogen).
Real-time PCR was performed using SYBR Green (Invitrogen) and
a Light Cycler (Roche) according to the manufacturer’s instruc-
tions. aP2 forward primer: CAAAATGTGTGATGCCTTTGTG; reverse
primer: CTCTTCCTTTGGCTCATGCC; PPARg forward primer: GCAT
GGTGCCTTCGCTGATGC; reverse primer: TACGTTTATCTGGTGTTT
CAT; Adipsin forward primer: GCTATCCCAGAATGCCCTCGTT; reverse
primer: CCACTTCTTTGTCCTCGTATTGC; PGC1a forward primer:
TGCGTGTGTGTATGTGTGTGTG; reverse primer: CCTTGTTCGTTCTG
TTCAGGTG. Alternatively, spontaneous NIH 3T3 L1 adipogenesis
was visualized after ﬁxation with 4% paraformaldehyd by oil red O
staining. Protein expression of stable transfectans was determined
by western blot.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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